Stable lipid-comprising drug delivery complexes and methods for their production
Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.
1. A noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide comprising polylysine, polyornithine, or polyarginine, or a polypeptide comprising polylysine, polyornithine, or polyarginine, and
wherein the noncovalent complex is formed by adding a nucleic acid to a solution comprising the at least one cationic lipid and the polycation.
2. The complex of claim 1 , wherein the ratio of lipid to nucleic acid ranges from 0.1 nmol to 200 nmol lipid per 1 μg nucleic acid.
3. The complex of claim 1 , wherein the ratio of lipid to nucleic acid ranges from 1 nmol to 25 nmol lipid per 1 μg nucleic acid.
4. The complex of claim 1 , wherein the polycation:nucleic acid ratio is 0.01 μg to 100 μg polycation to 1 μg nucleic acid.
5. A noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide or polypeptide comprising a histone, or a fragment thereof, wherein the molecular weight of the polycation is between 300 and 200,000 Daltons, and
wherein the complex is formed by adding a nucleic acid to a solution comprising the at least one cationic lipid and the polycation.
6. A noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide or polypeptide comprising a nuclear localization sequence, and
wherein the complex is formed by adding a nucleic acid to a solution comprising the at least one cationic lipid and the polycation.
7. The complex of claim 6 , wherein the cationic peptide is a synthetic peptide comprising a nuclear localization sequence of SV40 large T antigen.
8. A noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide or polypeptide comprising a protamine sulfate, and
wherein the complex is formed by adding a nucleic acid to a solution comprising the at least one cationic lipid and the polycation.
9. A noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is spermine or spermidine, and
wherein the complex is formed by adding a nucleic acid to a solution comprising the at least one cationic lipid and the polycation.
10. The complex of claim 9 , further comprising a neutral lipid.
11. The complex of claim 10 , wherein the neutral lipid is cholesterol or dioleoyl phosphatidylethanolamine (DOPE).
12. The complex of claim 9 , wherein the at least one cationic lipid is present as a cationic liposome, wherein the at least one cationic lipid is present in the liposome at a concentration of from 10 to 100 mole % of total liposomal lipid.
13. The complex of claim 12 , wherein the at least one cationic lipid is present in the liposome at a concentration of from 20 to 80 mole % of total liposomal lipid.
14. The complex of claim 12 , wherein the at least one cationic lipid is present in the liposome at a concentration of from 20 to 60 mole % of total liposomal lipid.
15. The complex of claim 1 , wherein the polycation has a molecular weight of from 300 to 200,000 Daltons.
16. A method for delivering nucleic acid to cells comprising contacting the cells with a noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide or a polypeptide comprising polylysine, polyornithine, or polyarginine, and
wherein the noncovalent complex is formed by adding a nucleic acid to a purified solution comprising the at least one cationic lipid and the polycation.
17. A method for delivering nucleic acid to cells comprising contacting the cells with a noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide or polypeptide comprising a histone, or a fragment thereof, wherein the molecular weight of the polycation is between 300 and 200,000 Daltons, and
wherein the complex is formed by adding a nucleic acid to a purified solution comprising the at least one cationic lipid and the polycation.
18. A method for delivering nucleic acid to cells comprising contacting the cells with a noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide or polypeptide comprising a nuclear localization sequence, and
wherein the complex is formed by adding a nucleic acid to a purified solution comprising the at least one cationic lipid and the polycation.
19. A method for delivering nucleic acid to cells comprising contacting the cells with a noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation is a cationic peptide or polypeptide comprising a protamine sulfate, and
wherein the complex is formed by adding a nucleic acid to a purified solution comprising the at least one cationic lipid and the polycation.
20. A method for delivering nucleic acid to cells comprising contacting the cells with a noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the complex comprising a nucleic acid, at least one cationic lipid and a polycation,
wherein the polycation comprises spermine or spermidine, and
wherein the complex is formed by adding a nucleic acid to a purified solution comprising the at least one cationic lipid and the polycation.
21. The complex of claim 5 , wherein the polycation is up to 500 amino acids in length.
22. The complex of claim 5 , wherein the polycation is 20 to 100 amino acids in length.
23. The complex of claim 5 , wherein the polycation is 20 to 35 amino acids in length.
24. The complex of claim 5 , wherein the polycation is 25 to 50 amino acids in length.
25. The method of claim 17 , wherein the polycation is up to 500 amino acids in length.
26. The method of claim 17 , wherein the polycation is 20 to 100 amino acids in length.
27. The method of claim 17 , wherein the polycation is 20 to 35 amino acids in length.
28. The method of claim 17 , wherein the polycation is 25 to 50 amino acids in length.
29. The complex of claim 1 , wherein the polycation is up to 500 amino acids in length.
30. The complex of claim 1 , wherein the polycation is 20 to 100 amino acids in length.
31. The complex of claim 1 , wherein the polycation is 20 to 35 amino acids in length.
32. The complex of claim 1 , wherein the polycation is 25 to 50 amino acids in length.
33. The method of claim 16 , wherein the polycation is up to 500 amino acids in length.
34. The method of claim 16 , wherein the polycation is 20 to 100 amino acids in length.
35. The method of claim 16 , wherein the polycation is 20 to 35 amino acids in length.
36. The method of claim 16 , wherein the polycation is 25 to 50 amino acids in length.